Proactive Investors - Run By Investors For Investors

Calithera Biosciences shares dip on $50 million secondary offering

The clinical stage biotechnology company will offer 12.5 million shares at $4 per share, 15% lower than its Tuesday close
Share document
Calithera Biosciences is a South San Francisco-based company focused on developing small-molecule treatments for cancer and other diseases

Calithera Biosciences Inc (NASDAQ:CALA) shares hit a stumbling block after the company announced the pricing of a $50 million secondary offering late Tuesday.

The clinical stage biotechnology company will offer 12.5 million shares at $4 per share, 15% lower than its Tuesday close.

Investors responded to the dilutive measure in kind, dropping the share price almost 13% to $4.13.

READ: Pressure BioSciences ultra high-pressure HUB platform shines in food safety studies

The offering is expected to close on June 21. In its Tuesday statement, the company did not specify what it would do with the proceeds.

Calithera Biosciences is a South San Francisco-based company focused on developing small-molecule treatments for cancer and other diseases.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

View full CALA profile View Profile

Related Articles

Enzymes under a microscope
April 29 2019
The Florida company applies its proprietary C1 gene expression platform to speed up the development of biologic vaccines, drugs at flexible commercial scales
Scientist at work
May 28 2019
CaPre, a potent form of Omega-3, has been shown to reduce triglycerides, but also lower 'bad cholesterol' levels, and raise 'good' ones
Oncoprex
October 18 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use